Related Experiment Video
Updated: Oct 22, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Synbiotics and Treatment of Asthma: A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial
Maryam Hassanzad1, Keyvan Maleki Mostashari1, Hosseinali Ghaffaripour1
1Pediatric Respiratory Diseases Research Center (PRDRC), National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Synbiotic compound Kidilact® reduced outpatient visits for pediatric asthma by 65% with minimal side effects. This suggests synbiotics can improve asthma management in children.
Area of Science:
- Pediatric Pulmonology
- Microbiome Research
- Clinical Nutrition
Background:
- Asthma is a prevalent chronic respiratory condition in children.
- Current treatments aim to manage symptoms and reduce exacerbations.
- The role of the gut microbiome in immune modulation and its potential in asthma management is an emerging area of research.
Purpose of the Study:
- To evaluate the efficacy and safety of a synbiotic compound, Kidilact®, in children with mild to moderate asthma.
- To compare the synbiotic intervention against a placebo in a pediatric asthma cohort.
Main Methods:
- A double-blinded, randomized, placebo-controlled trial.
- 100 children aged 12 or younger with mild to moderate asthma were enrolled.
- Intervention involved daily administration of Kidilact® or placebo for six months.
Main Results:
- The synbiotic group experienced significantly fewer outpatient visits (19 vs. 55) compared to the placebo group (P=0.001).
- No significant differences were observed in the frequency of asthma attacks or hospitalizations between groups.
- The synbiotic group reported fewer drug-induced side effects and higher overall satisfaction.
Conclusions:
- Synbiotic supplementation with Kidilact® appears to alleviate asthma symptoms in children, leading to reduced healthcare utilization.
- The intervention demonstrated a favorable safety profile with minimal adverse effects.
- Synbiotics show promise as an adjunct therapy for pediatric asthma management, potentially improving quality of life.
Background:
We examined the efficiency and safety of a specific synbiotic compound, brand name Kidilact®, in the treatment of asthma in children 12 years of age or younger.
Materials And Methods:
This double-blinded, randomized, placebo-controlled clinical trial was conducted in Tehran, Iran, from May 22, 2016, to May 21, 2017. One hundred children, 12 years of age or younger, who suffered from mild to moderate asthma were recruited in this study. The subjects were randomly divided into two groups; the experimental group received a sachet of Kidilact®, and the control group received a sachet of placebo once a day for six months. Both groups were compared in terms of the frequency of asthma attacks that were severe enough to require administration of fast-acting medications, the number of outpatient visits for asthma-related problems, and the frequency of hospitalization due to exacerbated symptoms of asthma.
Results:
There were fewer complaints of drug-induced side effects, e.g., vomiting, headache, stomachache, and diarrhea, exacerbated cough, and constipation in the experimental group than in the control group. Overall, a significantly greater number of participants in the experimental group were satisfied with the therapeutic intervention than those in the control group, as verified by the participants and their parents/guardians self-report. There was no significant difference between both groups in the frequency of asthma attacks and hospitalization due to exacerbated symptoms of asthma. The only significant difference between both groups was the count of outpatient visits. While the control group made 55 outpatient visits to the hospital, participants in the experimental group visited the hospital only 19 times (P=0.001).
Conclusion:
Results of our study indicates that synbiotic compound Kidilact® generally alleviates the symptoms of asthma in children of 12 years of age or younger, resulting in less frequent outpatient visits to the hospital due to asthma-related problems while rarely causing any side effects. Due to ease of use, the rarity of side effects, and their indirect positive effects on quality of life of asthmatic patients, we recommend that synbiotics be incorporated in regular treatment and management of children with asthma.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: